NCT06123858Terminated
Non-alcoholic Steatohepatitis Registry Platform Study
Source: ClinicalTrials.gov · Last updated 29 Jul 2026
Reason given: Following a reassessment of the company's pipeline priorities, the sponsor has elected to discontinue this project prior to its planned completion
Brief summary (registry, in English)
This is a multi-center, prospective, observational registry platform study aimed at describing the clinical characteristics and diagnosis and treatment patterns of Chinese patients with nonalcoholic steatohepatitis (NASH) with fibrosis.
- Status (registry)
- Terminated
- Study type
- Observational
- Enrollment
- 1122 (actual)
- First submitted
- 25 Oct 2023
- Start date
- 22 Nov 2023
- Primary completion date
- 17 Oct 2025
- Lead sponsor
- AstraZeneca
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT06123858
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of liver transplantation;
- Patients with bleeding tendency or coagulation dysfunction (for example, bleeding tendency, such as hemophilia, suspected hemangioma or suspected hydatid infection);
- Exclude liver diseases caused by the following causes: alcoholic steatohepatitis, drug-induced, viral or autoimmune hepatitis, primary hemochromatosis, α1-antitrypsin deficiency, hepatolenticular degeneration, hypothyroidism, inflammatory bowel disease, Cushing's syndrome, celiac disease, β lipoprotein deficiency, lipoatrophic diabetes mellitus, Mauriac syndrome, hypopituitarism, hypogonadism, polycystic ovarian syndrome;
- Have a history of malignant tumors in the past 5 years, excluding malignant tumors that have been cured by the investigator's judgment;
Other
- Pregnant or lactating women.
Who the study is looking for
- (1) Subjects must be between 18 and 75 years old when signing the informed consent form, and must have the ability to sign the consent form independently; (2) NASH patients who meet one of the following conditions:
- Liver biopsy was performed within 24 months before enrollment, and the pathological diagnosis was NASH and the fibrosis stage was F2 or above;
- FibroScan-AST (FAST) score ≥ 0.30 within 24 months before enrollment;
- There are any of the following evidences of fatty liver
- Controlled attenuation parameter (CAP) > 285 dB/m within 24 months before enrollment;
- Liver ultrasonography showed fatty liver within 24 months before enrollment;
- Magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) examination within 24 months before enrollment showed liver fat fraction ≥ 5%; and any of the following evidence of liver fibrosis
- <!-- -->
- Liver stiffness measurement (LSM) ≥ 7.5kPa by vibration-controlled transient elastography (VCTE) within 24 months before enrollment;
- The elasticity value of magnetic resonance elastography (MRE) examination within 24 months before enrollment is ≥2.93kPa;
- If there is no liver biopsy and no liver elastography equipment is available in the research center, FIB-4>1.3 (under 65 years old) or>2 (over 65 years old) within 3 months before enrollment.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (16)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - | Beijing | China | Unknown status |
| - | Changchun | China | Unknown status |
| - | Chengdu | China | Unknown status |
| - | Fuzhou | China | Unknown status |
| - | Guangzhou | China | Unknown status |
| - | Hangzhou | China | Unknown status |
| - | Inner Mongolia | China | Unknown status |
| - | Nanchang | China | Unknown status |
| - | Qingdao | China | Unknown status |
| - | Shanghai | China | Unknown status |
| - | Shenyang | China | Unknown status |
| - | Taiyuan | China | Unknown status |
| - | Tianjin | China | Unknown status |
| - | Wenzhou | China | Unknown status |
| - | Xi'an | China | Unknown status |
| - | Zhengzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.